WWR

Butterfly Network (BFLY.US) partnered with Bridge Neurotech in early October to develop non-invasive brain-computer interfaces using its ultrasound-on-chip technology, now commercialized through Mendaera's Focalist system. Q2 revenue rose 22.9% QoQ to USD 32.61 million amid a net margin deficit of -39.6%. Third-quarter results are scheduled for October 29.

Solana Company (HSDT.US) closed a USD 15 million direct offering at 5% above NAV, targeting Solana treasury expansion. CEO remarks highlighted China's intensified blockchain research with Hong Kong as a testing ground. Shares declined 10.54% weekly, trailing the S&P 500.

T3 Defense (DFNS.US) secured a USD 1.3 million European air defense order via subsidiary Rimon Agencies, marking its first overseas deal. The firm concurrently reduced its mixed shelf registration to USD 125 million. Stock tumbled 16% in September with 34.08% weekly volatility.

Westwater Resources (WWR.US) advanced its Alabama graphite project with over half of USD 245 million capex deployed and EXIM Bank financing secured. Analyst targets diverge: H.C. Wainwright projects USD 1.50 while Maxim Group holds USD 2.00.

Sionna Therapeutics (SION.US) initiated AscenSION CF Phase 2a trial for cystic fibrosis, following RA Capital's USD 21.85 million stake reduction. The study targeting F508del patients is set to launch in Q1 2027.

EQT Corporation (EQT.US) launched a USD 3.5 billion commercial paper program to bolster liquidity for natural gas operations. Q2 revenue fell 51.2% QoQ to USD 1.765 billion, with upstream contributing 77.04%. Q3 results due October 27.

Kinross Gold (KGC.US) trimmed 2026-2027 output forecasts by 2%-3% despite record operating margins from gold's strength. Q2 revenue totaled USD 2.238 billion, led by Brazil's Paracatu mine (31.3%). UBS maintains USD 28 target.

INNIO N.V. (INIO.US) extended Aggreko partnership through 2031, securing 450MW Jenbacher engine supply. Q2 revenue jumped 42% YoY to USD 937.7 million, with equipment sales at 60.71%. Shares surged 12.49% on October 6.

Leveraged ETFs MRAL.US and UCYB.US showed no product updates in recent weeks, with financial news absent for 30 days.